PMID- 31607204
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1814-1412 (Electronic)
IS  - 1562-2975 (Linking)
VI  - 21
IP  - 4
DP  - 2020 Apr
TI  - A prospective open-label trial of long-acting liquid methylphenidate for the 
      treatment of attention deficit/hyperactivity disorder in intellectually capable 
      adults with autism spectrum disorder.
PG  - 274-290
LID - 10.1080/15622975.2019.1679392 [doi]
AB  - Objectives: This treatment trial is aimed at assessing the short-term 
      tolerability and efficacy of liquid-formulation extended-release methylphenidate 
      (MPH-ER) for the treatment of attention deficit/hyperactivity disorder (ADHD) in 
      adults with high-functioning autism spectrum disorder (HF-ASD).Methods: A 6-week 
      open-label trial (ClinicalTrials.gov: NCT02096952) was conducted in 15 HF-ASD 
      adults (mean age 24.9 +/- 4.6; male, 12 (80%)) suffering from moderate-severe ADHD. 
      MPH-ER was administered based on a flexible titration schedule. Efficacy was 
      assessed on clinician- and self-rated measures. Tolerability was assessed by 
      documenting treatment-emergent adverse events (AEs) and other safety 
      measures.Results: Short-term MPH-ER treatment was associated with significant 
      improvement in ADHD severity (Adult ADHD Investigator Symptom Report Scale 
      (AISRS) mean change (MC), -22.8 +/- 8.8, P < 0.001; Adult ADHD Self-Report Scale 
      (ASRS) MC, -8.2 +/- 15.3, P < 0.001). Twelve (80%) participants were deemed 
      responders, based on >/=30% reduction in AISRS score and an ADHD Clinical Global 
      Impression-Improvement score </=2. MPH-ER was well-tolerated (treatment-limiting 
      AEs, 1/15; severe AEs, 1/15) at mean dose of 48.7 +/- 15 mg/day. AEs were transient 
      and experienced by 13/15 (87%) participants at mild to moderate severity. 
      Frequently reported AEs were as typically expected (headache (53%), insomnia 
      (33%), anxiety (33%), decreased appetite (27%)).Conclusions: Our findings suggest 
      that MPH-ER is effective and well-tolerated in the treatment of ADHD in HF-ASD 
      adults.
FAU - Joshi, Gagan
AU  - Joshi G
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
FAU - DiSalvo, Maura
AU  - DiSalvo M
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
FAU - Wozniak, Janet
AU  - Wozniak J
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
FAU - Ceranoglu, T Atilla
AU  - Ceranoglu TA
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
FAU - Yule, Amy
AU  - Yule A
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
FAU - Surman, Craig
AU  - Surman C
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
FAU - Fried, Ronna
AU  - Fried R
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
FAU - Galdo, Maribel
AU  - Galdo M
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
FAU - Hoskova, Barbora
AU  - Hoskova B
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
FAU - Belser, Abigail
AU  - Belser A
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
FAU - Biederman, Joseph
AU  - Biederman J
AD  - Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum 
      Disorder, Massachusetts General Hospital, Boston, MA, USA.
AD  - Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02096952
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191219
PL  - England
TA  - World J Biol Psychiatry
JT  - The world journal of biological psychiatry : the official journal of the World 
      Federation of Societies of Biological Psychiatry
JID - 101120023
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Delayed-Action Preparations)
RN  - 207ZZ9QZ49 (Methylphenidate)
SB  - IM
MH  - Adult
MH  - *Attention Deficit Disorder with Hyperactivity/complications/drug therapy
MH  - *Autism Spectrum Disorder/complications
MH  - *Central Nervous System Stimulants/adverse effects/therapeutic use
MH  - Delayed-Action Preparations/therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - *Methylphenidate/adverse effects/therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - ADHD
OT  - ASD
OT  - methylphenidate
OT  - open-label
OT  - psychopharmacology
EDAT- 2019/10/15 06:00
MHDA- 2021/03/12 06:00
CRDT- 2019/10/15 06:00
PHST- 2019/10/15 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
PHST- 2019/10/15 06:00 [entrez]
AID - 10.1080/15622975.2019.1679392 [doi]
PST - ppublish
SO  - World J Biol Psychiatry. 2020 Apr;21(4):274-290. doi: 
      10.1080/15622975.2019.1679392. Epub 2019 Dec 19.